Evolent Health, Inc. (EVH) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 7 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Tue, Feb 24, 2026 | after close | 55 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 20, 2025 | after close | 51 | 8-K |
What they guided beta
| Q3 FY2026 | "Adjusted Results Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data): For the Three Months Ended September 30, 2026 2025 Adjusted cost of revenue $ 635,107 $ 378,518 Adjusted selling, general and administrative expenses $ 56,003 $ 62,060 Adjusted EBITDA $ 34,257 $ 38,955 Adjusted EBITDA margin 4.7 % 8.1 % Adjusted income attributable to common shareholders $ 7,296 $ 5,630 Adjusted income per share attributable to common shareholders: Basic and diluted $ 0.06 $ 0.05 2 Business Outlook The Company does not believe it can meaningfully rec" exhibit |
| Q3 FY2026 | "Full Year 2026 Guidance Incorporating its year-to-date performance, the Company is reiterating its 2026 revenue guidance range to $2.6 billion to $2.7 billion and raising its Adjusted EBITDA range to $130.0 million to $135.0 million." exhibit |
| Q3 FY2026 | "Additional Outlook Information The Company expects to deploy $26 million to $28 million in cash for capitalized expenditures during 2026." exhibit |
| Q2 FY2026 | "Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, “We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow." exhibit |
| Q2 FY2026 | "We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure." Mario Ramos, Chief Financial Officer of Evolent stated, “Looking ahead to 2027, based on contracts in place today, upcoming launches scheduled and the strong continuing demand for our oncology solution, we expect to see revenue growth of over 25% compared to 2026." exhibit |
| Q2 FY2026 | "We expect the midpoint of our 2027 Adjusted EBITDA outlook will be at or above $150 million driven by expected improved Performance Suite care margins and a strong focus on expense reductions, despite significant continued industry headwinds from Medicaid and other client specific membership attrition." exhibit |
| Q2 FY2026 | "We also expect improved cash flow conversion, which, together with targeted debt reduction initiatives we are currently evaluating, we believe provides a clear path to addressing our capital structure and enhancing financial flexibility." Highlights include (dollars in thousands, except for average PMPM fees and revenue per case): For the Three Months Ended June 30, 2026 2025 Financial Results: Revenue $ 652,520 $ 444,328 Net loss attributable to common shareholders of Evolent Health, Inc. $ (28,364) $ (51,090) Net loss margin (4.3) % (11.5) % Adjusted EBITDA $ 28,050 $ 37,547 Adjusted EBITDA " exhibit |
| Q2 FY2026 | "We currently expect this business to launch by December 2026, subject to certain regulatory approvals, and generate approximately $300 million in annualized revenue." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/EVH
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/EVH
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/EVH/"><img src="https://veritasdata.dev/embed/EVH.svg" alt="EVH earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/EVH/)
Script
<script async src="https://veritasdata.dev/embed/EVH.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/EVH"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.